CADSET: Chronic Airway DiSeases Early sTratification

CRC Chairs:
Alvar Agusti (Hospital Clinic de Barcelona, Respiratory Institute, University of Barcelona, Barcelona, Spain)
Wisia Wedzicha (Imperial College London (ICL), London, United Kingdom)
Rosa Faner (Centro de Investigación Biomédica en Red (CIBER), Barcelona, Spain)
Erik Melén (Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden)


CADSET is a pan-European network committed to promoting clinical research in chronic airway diseases. The overarching working hypothesis of CADSET is that Asthma and Chronic Obstructive Pulmonary Disease (COPD) represents a continuum of heterogeneous chronic airway diseases that share clinical, functional, imaging and/or biological mechanisms (i.e endotypes), that can be identified by appropriately validated biomarkers, which may constitute novel therapeutic targets.

Multi-level (clinical, functional, imaging and molecular) profiling of well-characterized patients with chronic airways disease, spanning the spectrum of asthma and COPD, that considers both peak lung function achieved in early adulthood and the rate of lung function decline, may lead to the identification of distinct endotypes (and appropriate biomarkers) which may, in turn, inform a mechanism-based disease classification and a more personalized treatment of patients with chronic airways diseases.

Specific aims

  • To generate a multi-centre, multi-disciplinary platform that facilitates the investigation of lung function trajectories on the clinical presentation of chronic airway diseases.
  • To create a registry of currently available cohorts (and associated data and/or bio-banks) in order to launch joint meta-analyses.
  • To share expertise and resources, as well as create common research protocols to enable the comparison and integration of data across different cohorts.
  • To identify distinct biological mechanisms (i.e. endotypes), and associated biomarkers, underlying different lung function trajectories in order to move COPD assessment and therapy towards a precision medicine framework.
  • To raise public and private funding for these projects.


To achieve those aims five working groups have been composed and are the scientific drivers of CADSET.

  • WG1 – Registry: To develop a registry of sharable consortium resources (existing cohorts and data (clinical, imaging, samples, omics and bio-bank)) and to create common research protocols (SOP).
  • WG2 – From conception to 25 years: To investigate the phenotypes and endotypes of suboptimal peak lung function at early adulthood (<25 years).
  • WG3 – From 25 years to 50 years: To investigate the endotypes and clinical heterogeneity of early lung function decline as well as potential therapeutic responses (precision medicine).
  • WG4 – From 50 years onwards: Integrating multilevel data on well-defined populations with “asthma” or “COPD” in order to understand phenotypes, endotypes and biomarkers of chronic airway diseases.
  • WG5 – Building the long-life trajectories: To integrate the age-related results of WG2, WG3 and WG4.


The Stakeholder Board offers an open forum composed by a strong and worthy partnership between the different stakeholders groups e.g clinician researchers, scientific experts, funding partners and patient advisors where project proposals and results are openly discussed. The Governance Committee forms the core deciding body of CADSET and is composed by the CRC Chairs, the Working Leads, patient and will drive the research agenda. An External international advisory board (EAB) of leading experts in the field will assess and input on the research agenda.

Bringing together the expertise of all these groups is certain to provide the means to achieve the goals of CADSET.


If you are interested in more information about CADSET or would like to join the network, please contact

Financially supported by:

 - Preview Image
 - Preview Image
 - Preview Image
 - Preview Image
 - Preview Image